14 Feb 2019
Posted by Andrew Kantor
While our own Greg Reybold is the best place to keep up with pharmacy-related bills in the legislature, Georgia Health News has a great piece covering the major healthcare bills being considered.
Do you know a Georgia pharmacy professional who deserves recognition for his or her work?
Perhaps an amazing young pharmacist, an outstanding innovator, or someone who is a paragon of pharmacy excellence?
Or maybe someone who has spent a lifetime in service of others and the profession of pharmacy?
Whomever it is, we need you to tell us! It’s time to nominate people for the 2019 Georgia Pharmacy Awards. And the deadline is this Friday, February 15.
These are awards created by your association, but its your input — your nominations — that give them meaning. And it starts with nominations.
Visit our awards page at GPhA.org/awards for more information on award criteria and to make your nominations. Deadline for submissions is February 15, 2019.
Piedmont Fayette Hospital in Fayetteville was named one of the top one percent (!) of hospitals in America by HealthGrades — that places it as one of the 50 best hospitals in the country.
Emory University Hospital and Emory University Hospital Midtown, both in Atlanta, were named to the top two percent, while Emory Saint Joseph’s (Atlanta), Piedmont Hospital (Atlanta), Piedmont Newnan Hospital (Newnan) and Wellstar Kennestone Hospital (Marietta) all made the top five percent.
The FDA is planning to start taking a harder look at dietary supplements — and that’s not just sending out occasional warning letters. Besides stronger enforcement of “don’t put secret prescription meds into products” rules, it’s considering tighter restrictions and clearer disclosures.
An FDA committee has endoresed full approval of esketamine, which, you can tell from the name, is based on everyone’s favorite animal tranquilizer (and potential depression treatment), ketamine.
If it gets FDA approval, esketamine “is expected to be used in combination with antidepressants, but the latter can take a month or two to take effect. Esketamine, on the other hand, might have an effect within hours or days.”
Although he was “disturbed to hear” of commercial-insurance patients having to use step therapy when they switch providers, when it comes to Medicare Part B plans, HHS Secretary Alex Azar says he supports step therapy and prior authorization, claiming it keeps costs down.